Business · 16/03/2023Updated: 10/17/2026 · 1 min read
Fresenius Kabi USA, LLC, et al. Withdraw Approval of Six Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) is withdrawing approval of six abbreviated new drug applications (ANDAs) from multiple applicants, following written notifications that the drug products are no longer being marketed.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →